Gossamer Bio, Inc. (GOSS) stock
GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.72−0.51 (-4.54%)
Close on Nov 20, 2026Market cap $5.24BP/E –Yield –
Gossamer Bio free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Gossamer Bio's free cash flow for the twelve months ending Jun 30, 2026 was -$162.63M. For fiscal 2025 it was -$171.35M. The highest annual figure on record is -$3.47M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$171.35M | – |
| FY2024 | Dec 31, 2024 | -$3.47M | – |
| FY2023 | Dec 31, 2023 | -$159.16M | – |
| FY2022 | Dec 31, 2022 | -$187.44M | – |
| FY2021 | Dec 31, 2021 | -$190.44M | – |
| FY2020 | Dec 31, 2020 | -$177.86M | – |
| FY2019 | Dec 31, 2019 | -$147.80M | – |
| FY2018 | Dec 31, 2018 | -$54.53M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$39.42M | – |
| Q1 FY2026 | Mar 31, 2026 | -$38.72M | – |
| Q4 FY2025 | Dec 31, 2025 | -$48.31M | – |
| Q3 FY2025 | Sep 30, 2025 | -$36.17M | – |
| Q2 FY2025 | Jun 30, 2025 | -$47.11M | -140.5% |
| Q1 FY2025 | Mar 31, 2025 | -$39.75M | – |
| Q4 FY2024 | Dec 31, 2024 | -$35.48M | – |
| Q3 FY2024 | Sep 30, 2024 | -$32.03M | – |
| Q2 FY2024 | Jun 30, 2024 | $116.35M | – |
| Q1 FY2024 | Mar 31, 2024 | -$52.30M | – |
| Q4 FY2023 | Dec 31, 2023 | -$33.42M | – |
| Q3 FY2023 | Sep 30, 2023 | -$34.49M | – |
| Q2 FY2023 | Jun 30, 2023 | -$38.25M | – |
| Q1 FY2023 | Mar 31, 2023 | -$52.99M | – |
| Q4 FY2022 | Dec 31, 2022 | -$47.83M | – |
| Q3 FY2022 | Sep 30, 2022 | -$37.03M | – |
| Q2 FY2022 | Jun 30, 2022 | -$48.94M | – |
| Q1 FY2022 | Mar 31, 2022 | -$53.64M | – |
| Q4 FY2021 | Dec 31, 2021 | -$40.59M | – |
| Q3 FY2021 | Sep 30, 2021 | -$42.56M | – |
| Q2 FY2021 | Jun 30, 2021 | -$47.59M | – |
| Q1 FY2021 | Mar 31, 2021 | -$59.70M | – |
| Q4 FY2020 | Dec 31, 2020 | -$36.99M | – |
| Q3 FY2020 | Sep 30, 2020 | -$45.23M | – |
| Q2 FY2020 | Jun 30, 2020 | -$42.84M | – |
| Q1 FY2020 | Mar 31, 2020 | -$52.81M | – |
| Q4 FY2019 | Dec 31, 2019 | -$44.67M | – |
| Q3 FY2019 | Sep 30, 2019 | -$36.82M | – |
| Q2 FY2019 | Jun 30, 2019 | -$38.19M | – |
| Q1 FY2019 | Mar 31, 2019 | -$28.12M | – |
| Q4 FY2018 | Dec 31, 2018 | -$25.35M | – |
| Q3 FY2018 | Sep 30, 2018 | -$17.23M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.74M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.22M | – |
See a number that looks wrong?